Core Insights - Kenvue Inc. (NYSE:KVUE) is facing significant legal challenges that could impact its market performance, leading to a Neutral rating from Johnson Rice with a stock price of $14.59 [1][6] Legal Challenges - Texas Attorney General Ken Paxton has filed a lawsuit against Kenvue and Johnson & Johnson, alleging concealment of information regarding Tylenol's potential links to autism and ADHD, raising safety concerns about the medication [2] - The lawsuit specifically accuses Kenvue of misleading pregnant women about the risks associated with Tylenol, claiming deceptive marketing practices that promoted the drug as safe during pregnancy [3] Market Performance - KVUE's stock price is currently at $14.64, reflecting a decrease of approximately 2.95% from the previous day, with a trading range between $14.56 and $14.93 [4] - Over the past year, KVUE has experienced significant volatility, with a high of $25.17 and a low of $14.05 [4] - The company's market capitalization is approximately $28.09 billion, with a trading volume of 7.52 million shares, indicating challenges in maintaining investor confidence [5]

The makers of Tylenol, Johnson & Johnson JNJ.N and Kenvue KVUE.N, were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug’s links to autism and attention deficit hyperactivity disorder.Paxton, a Republican, sued five weeks after Republican President Donald Trump said using Tylenol during pregnancy can cause autism in children. Trump is not a doctor, and his claim is unproven and not backed by scientific evidence. Johnson & Johnson sold Tylenol for more than s ...

Texas Attorney General Ken Paxton announced Tuesday that he is suing the two pharmaceutical manufacturers for allegedly deceptively marketing Tylenol to pregnant mothers despite knowing of links to autism and other disorders. Paxton sued the makers of Tylenol – Kenvue and its former parent company Johnson & Johnson – over the alleged deceptive marketing. He claims that the companies knew early exposure to the active ingredient in Tylenol, acetaminophen, was linked to autism and attention deficit hyperactivi ...

The makers of Tylenol, Johnson & Johnson and Kenvue , were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug's links to autism and attention deficit hyperactivity disorder. ...

Core Viewpoint - The lawsuit claims that the manufacturer of Tylenol engaged in misleading marketing practices by promoting the product as safe for use during pregnancy [1] Group 1 - The suit alleges deceptive marketing practices by the Tylenol maker [1]

Core Insights - Kenvue Inc. (NYSE: KVUE) is a significant player in the consumer health industry, with a current stock price of $15 and a market capitalization of approximately $28.79 billion, indicating its substantial market presence [1][4][5] - Jefferies has set a price target of $23 for KVUE, suggesting a potential increase of about 53.33% from its current price, reflecting confidence in the company's future performance [1][5] - KVUE is scheduled to release its third quarter 2025 financial results on November 6, 2025, which will provide insights into the company's financial health and could influence investor sentiment [2][5] Stock Performance - KVUE's stock has shown a slight decrease of 0.60%, with a change of $0.09, and has experienced fluctuations with a daily low of $14.99 and a high of $15.28 [3] - Over the past year, KVUE's stock has seen a high of $25.17 and a low of $14.05, indicating volatility in its stock performance [3] Market Metrics - The trading volume for KVUE's stock is 12.42 million shares on the NYSE, indicating active investor interest [4]

Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty ImagesSOPA Images/LightRocket via Getty ImagesKenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its stock price in recent months. The shares are currently priced around $15, which is more than 65% lower than their highs in 2023, as investors contend with legal uncertainties, management changes, and slowing sales growth. The question is whether this decline represents a wo ...

Core Points - Kenvue Inc. will announce its third quarter 2025 financial results before the market opens on November 6, 2025 [1] - The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results [1] - Access to the conference call can be made by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations [1] - A live webcast of the conference call will be available at investors.kenvue.com, with a replay made available [1]

If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them.A big dividend yield is nice to see, but it shouldn't be the only thing you look at when buying a stock. The actual business behind the yield is, in fact, more important. That's why you'll need to think carefully about your risk tolerance when you look at high-yielding healthcare stocks like Kenvue (KVUE 0.60%), Pfizer (PFE +0.36%), and Omega Healthcare (OHI 0.49%). Her ...

Core Viewpoint - The article highlights three high-yield healthcare stocks: Kenvue, Medtronic, and Pfizer, each with distinct characteristics and investment considerations. Group 1: Kenvue - Kenvue, spun off from Johnson & Johnson, operates in the consumer staples sector with well-known brands like Band-Aid and Tylenol [4][5]. - The stock has faced negative attention due to health concerns related to Tylenol, leading to a significant price drop and an increased dividend yield of 5.5% [7][8]. - Despite recent performance challenges and lowered guidance, Kenvue is expected to navigate through this period while rewarding investors [9]. Group 2: Medtronic - Medtronic is approaching a significant milestone with 48 consecutive years of dividend increases, just two years shy of becoming a Dividend King [10]. - The company is undergoing a business overhaul, including a spinoff of its diabetes division, which is expected to enhance earnings and focus on more profitable areas [11]. - Medtronic's current dividend yield is around 3%, and it is seen as a stable investment option as the company works to regain investor confidence [12]. Group 3: Pfizer - Pfizer offers the highest yield among the three at nearly 7%, but its dividend payout ratio is close to 100%, raising concerns about sustainability [13]. - The company is pursuing a significant acquisition of Metsera to bolster its drug pipeline, which reflects its commitment to long-term growth despite current challenges [16]. - Viewing Pfizer as a turnaround stock may present an opportunity, as the high yield indicates market skepticism, but the company has a history of resilience [15][17].